Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$146.14 USD

146.14
6,182,473

-0.68 (-0.46%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $145.99 -0.15 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (198 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively

Johnson & Johnson (JNJ) Rises But Trails Market: What Investors Should Know

Johnson & Johnson (JNJ) concluded the recent trading session at $160.98, signifying a +0.12% move from its prior day's close.

Why Is Johnson & Johnson (JNJ) Down 0.2% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts

In the most recent trading session, Johnson & Johnson (JNJ) closed at $158.68, indicating a +0.52% shift from the previous trading day.

Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag

Halozyme's (HALO) fourth-quarter 2023 earnings meet estimates, while revenues miss the same.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Is FlexShares Quality Dividend ETF (QDF) a Strong ETF Right Now?

Smart Beta ETF report for QDF

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Style Box ETF report for HDV

Sweta Killa headshot

A Look at Pharma ETFs After Q4 Earnings

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

The Zacks Analyst Blog Highlights Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health

Johnson & Johnson, Disney, Uber, Goldman Sachs and Elevance Health are included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Johnson & Johnson, Walt Disney & Uber

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), The Walt Disney Company (DIS) and Uber Technologies, Inc. (UBER).

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs

AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q4 Earnings Due on Jan 31: NVO, NVS & GSK

Let's look at three biotech/drug companies, NVO, NVS and GSK, slated to release quarterly results on Jan 31.

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation

J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ Reports Q4 Earnings, SNY Inks M&A Deal With INBX

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sanofi (SNY) is set to acquire Inhibrx's (INBX) rare disease pipeline candidate, INBRX-101.

Stock Market News for Jan 24, 2024

Wall Street closed mixed on Tuesday on strong to mixed quarterly earnings.

Ethan Feller headshot

3 Stocks to Consider After Beating Earnings Estimates

Q4 earnings results are rolling in, and these stocks showed strong performance

J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.

Mixed Q4 Earnings Report

Mixed Q4 Earnings Report

Mark Vickery headshot

Q4 Earnings for J&J, Procter, GE & More

Pre-market trading fortunes are mixed for this morning's reportees, including JNJ, PG, GE, MMM and DHI.

Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.